EGFR (C797A)

EGFR · Variant type: point · HGVS: p.C797A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Afatinib	100.0%	0.0%	98.50
2	Gefitinib	100.0%	0.0%	99.25
3	Lapatinib	100.0%	0.0%	99.25
4	Dacomitinib	99.9%	0.1%	97.99
5	Bosutinib	99.9%	0.1%	87.22
6	Neratinib	99.8%	0.2%	93.18
7	Canertinib	99.8%	0.2%	96.49
8	Fostamatinib	99.3%	0.7%	96.74
9	Brigatinib	99.1%	0.9%	82.96
10	Erlotinib	99.1%	0.9%	99.75
11	Vandetanib	98.6%	1.4%	95.74
12	Defactinib	95.4%	4.6%	92.68
13	Dasatinib	95.4%	4.6%	87.97
14	Mobocertinib	88.5%	11.5%	97.22
15	Ibrutinib	87.8%	12.2%	94.74
16	Ponatinib	87.3%	12.7%	78.23
17	Pacritinib	85.5%	14.5%	88.64
18	Pirtobrutinib	83.9%	16.1%	99.49
19	Alectinib	82.2%	17.8%	95.49
20	Gilteritinib	69.1%	30.9%	88.97
21	Tivozanib	53.8%	46.2%	92.42
22	Lorlatinib	52.0%	48.0%	97.24
23	Osimertinib	48.4%	51.6%	97.24
24	Avapritinib	46.4%	53.6%	97.73
25	Fedratinib	44.6%	55.4%	96.21

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Afatinib	100.0%	100.0%	+0.0%
Gefitinib	100.0%	99.9%	+0.1%
Lapatinib	100.0%	99.2%	+0.8%
Dacomitinib	99.9%	99.8%	+0.1%
Bosutinib	99.9%	99.3%	+0.6%
Neratinib	99.8%	100.0%	-0.2%
Canertinib	99.8%	98.4%	+1.4%
Fostamatinib	99.3%	97.8%	+1.6%
Brigatinib	99.1%	98.5%	+0.6%
Erlotinib	99.1%	99.4%	-0.4%
Vandetanib	98.6%	99.3%	-0.7%
Defactinib	95.4%	94.6%	+0.9%
Dasatinib	95.4%	97.9%	-2.6%
Mobocertinib	88.5%	100.0%	-11.5%
Ibrutinib	87.8%	99.3%	-11.5%
Ponatinib	87.3%	—	—
Pacritinib	85.5%	—	—
Pirtobrutinib	83.9%	—	—
Alectinib	82.2%	—	—
Gilteritinib	69.1%	91.0%	-21.9%
Tivozanib	53.8%	—	—
Lorlatinib	52.0%	—	—
Osimertinib	48.4%	99.1%	-50.7%
Avapritinib	46.4%	—	—
Fedratinib	44.6%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.9ms